• Cytek Biosciences posted Q1 2026 revenue of USD 44.1 million, up 6% year over year, while net loss widened to USD 18.9 million.
• Operating loss deepened to USD 18.5 million as operating expenses climbed 13% to USD 39.7 million, driven primarily by litigation-related expenses, outside consulting costs, and bad debt reserves.
• Service revenue rose 15% to USD 15.4 million, lifting total recurring revenue to USD 18.4 million; recurring revenue represented 35% of trailing-12-month revenue, up from 31% a year earlier.
• Installed base expanded to 3,789 instruments with 125 units added during quarter.
• Cytek reaffirmed 2026 revenue guidance of USD 205 million to USD 212 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071605PRIMZONEFULLFEED9715966) on May 07, 2026, and is solely responsible for the information contained therein.